Two Sigma Advisers’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Two Sigma Advisers’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,152,900	Closed	-$78.5M	–	2795
2022 Q3	$78.5M	Buy	1,152,900 +818,800	+245%	+$45.2M	0.23%	110
2022 Q2	$10.7M	Buy	334,100 +245,900	+279%	+$7.2M	0.03%	483
2022 Q1	$3.06M	Buy	+88,200	New	+$2.64M	0.01%	1033
2020 Q3	–	Sell	-9,700	Closed	-$612K	–	2702
2020 Q2	$612K	Sell	9,700 -6,400	-40%	-$439K	﹤0.01%	1798
2020 Q1	$823K	Sell	16,100 -64,196	-80%	-$4.3M	﹤0.01%	1585
2019 Q4	$6.38M	Buy	+80,296	New	+$4.76M	0.01%	749

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Two Sigma Advisers's GBT Position: Q4 2022 in Review

Two Sigma Advisers sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,152,900 shares — an estimated $78.5M sold.

Two Sigma Advisers first reported a position in GBT in Q4 2019 and held it in 6 quarters. The position peaked at $78.5M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Two Sigma Advisers reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Two Sigma Advisers sold 1,152,900 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $78.5M.
Two Sigma Advisers first reported a position in Global Blood Therapeutics, Inc. in Q4 2019 and held it in 6 quarters.
Two Sigma Advisers's Global Blood Therapeutics, Inc. position peaked at $78.5M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.